Novo Nordisk (NOVOB DC) says Wegovy delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity

Novo Nordisk's announcement about Wegovy shows strong weight loss potential across various menopause stages, alongside cardiovascular and migraine benefits.

Newsquawk StaffPublished On the live feed at 3 more headlines followed before this page went public
Newsquawk headlinesUTC

ECB's Elderson "Boosting prosperity through deeper integration"

UK PM Starmer said in the "cabinet that he won’t discuss the elections or his leadership, and that he will only speak to cabinet ministers about that individually", Times' Kendix reports; after the meeting he refused to meet them individually

Novo Nordisk (NOVOB DC) says Wegovy delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity

UK PM Starmer has asked the Cabinet to come and see him individually, Bloomberg sources state

Fitch affirms Hong Kong at "AA-"; outlook stable

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This data could positively influence market sentiment for Novo Nordisk, highlighting the drug's broader health impacts and likely broadening its market appeal, which is significant for its growth outlook.

Related headlines

The whole workspace, free to try.

Try it free